Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The case for allele-specific recognition by the TCR.

Scandinavian journal of immunology·2019
Same author

The real "danger" lies in the failure to confront fundamentals.

Scandinavian journal of immunology·2018
Same author

Exploring the elements for a successful immune offense against cancer.

Experimental and molecular pathology·2018
Same author

Rationalizing the path to a universal graft recipient.

Immunologic research·2018
Same author

History of the antibody workshops.

Immunologic research·2017
Same author

An observation that illustrates most T cell receptor structure-function relationships.

Immunologic research·2017
Same journal

Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

European journal of immunology·2026
Same journal

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same journal

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European journal of immunology·2026
Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026
Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

“Allorestriction” should be distinguished from “alloreactivity”.

Melvin Cohn1

  • 1Conceptual Immunology Group, The Salk Institute for Biological Studies, La Jolla, CA, USA. cohn@salk.edu

European Journal of Immunology
|January 4, 2012
PubMed
Summary
This summary is machine-generated.

The study differentiates alloreactivity from allorestriction in T-cell receptor (TCR) signaling. It proposes that alloreactivity, triggered by MHC recognition, is distinct from allorestriction, which is peptide-specific, challenging existing models.

More Related Videos

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm
12:12

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm

Published on: May 14, 2014

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

Related Experiment Videos

Last Updated: May 26, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm
12:12

Irrelevant Stimuli and Action Control: Analyzing the Influence of Ignored Stimuli via the Distractor-Response Binding Paradigm

Published on: May 14, 2014

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

Area of Science:

  • Immunology
  • Molecular Biology
  • T-cell signaling

Background:

  • T-cell receptor (TCR) recognition of peptide-MHC complexes is fundamental to adaptive immunity.
  • Distinguishing between allorestriction and alloreactivity is crucial for understanding TCR-ligand interactions.
  • Current models of TCR-ligand interaction offer different perspectives on these phenomena.

Purpose of the Study:

  • To clarify the distinction between allorestriction and alloreactivity in TCR signaling.
  • To evaluate the validity of the Centric Model versus the Tritope Model for TCR-ligand interactions.
  • To analyze data supporting the proposed distinction and its implications.

Main Methods:

  • Theoretical modeling of TCR-ligand interactions (Centric Model vs. Tritope Model).
  • Analysis of existing experimental data related to TCR signaling.
  • Comparative evaluation of model predictions against observed phenomena.

Main Results:

  • The Tritope Model posits two distinct TCR signaling interactions: allorestriction (peptide-specific) and alloreactivity (peptide-unspecific).
  • Alloreactivity is triggered by recognition of the allo-MHC-encoded restricting element allele.
  • Alloreactivity is incompatible with the Centric Model, suggesting it may not exist under that framework.

Conclusions:

  • The distinction between allorestriction and alloreactivity is critical and depends on the chosen model of TCR-ligand interaction.
  • The Tritope Model provides a framework that accommodates both allorestriction and alloreactivity.
  • Further analysis of experimental data is needed to definitively validate the Tritope Model and the existence of alloreactivity.